MediciNova, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
MNOV Nasdaq 2830 medicinova.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for MediciNova, Inc.

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients - Jul 15th, 2026 6:00 am
MediciNova CEO Provides Shareholder Update - Jun 30th, 2026 6:00 am
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight - Jun 8th, 2026 11:00 am
MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment - Jun 8th, 2026 6:00 am
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) - May 26th, 2026 5:00 pm
We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth - May 16th, 2026 6:28 am
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation - Apr 27th, 2026 5:00 pm
Super Micro downgraded, MongoDB upgraded: Wall Street's top analyst calls - Mar 23rd, 2026 7:44 am
MediciNova to Participate at the 38th Annual ROTH Conference - Mar 16th, 2026 5:00 am
MediciNova: Q4 Earnings Snapshot - Feb 20th, 2026 4:40 am
Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share Worth USD 1964 Million by 2035 at 11.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - Feb 19th, 2026 1:30 am
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients - Jan 29th, 2026 4:00 pm
ATA Creativity Global Among 3 Promising Penny Stocks - Jan 20th, 2026 5:05 am
2026 New Year’s Greetings from the CEO - Jan 6th, 2026 7:00 am
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy - Dec 18th, 2025 4:00 am
Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsight - Dec 9th, 2025 3:31 pm
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND - Dec 8th, 2025 4:00 am
Message from the CEO to MediciNova Shareholders - Dec 1st, 2025 4:00 pm
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor - Nov 18th, 2025 4:00 am
MediciNova: Q3 Earnings Snapshot - Nov 12th, 2025 3:22 pm